DNA- and RNA-aptamers binding the soluble interleukin-6-receptor

The invention concerns DNA- and RNA-aptamers with high affinity and specificity for the human soluble IL-6-receptor with no or very low immunogenicity. These aptamers are very promising substances to treat or prevent diseases involving the IL-6-receptor, such as inflammation, cancer or infections. Furthermore, they can be easily and cost-efficiently produced and stored.

Further Information: PDF

Patent- und Verwertungsagentur für die Wissenschaftlichen Einrichtungen in Schleswig-Holstein GmbH (PVA SH)
Phone: +49 (0)431/8009937

Contact
Dr. Alexandra Baumgartner

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

All latest news from the category: Technology Offerings

Back to home

Comments (0)

Write a comment

Newest articles

NASA: Mystery of life’s handedness deepens

The mystery of why life uses molecules with specific orientations has deepened with a NASA-funded discovery that RNA — a key molecule thought to have potentially held the instructions for…

What are the effects of historic lithium mining on water quality?

Study reveals low levels of common contaminants but high levels of other elements in waters associated with an abandoned lithium mine. Lithium ore and mining waste from a historic lithium…

Quantum-inspired design boosts efficiency of heat-to-electricity conversion

Rice engineers take unconventional route to improving thermophotovoltaic systems. Researchers at Rice University have found a new way to improve a key element of thermophotovoltaic (TPV) systems, which convert heat…